Beigene Ltd (NASDAQ:BGNE)‘s stock had its “buy” rating reiterated by stock analysts at Maxim Group in a research note issued on Thursday. They currently have a $52.00 price objective on the stock. Maxim Group’s price objective would indicate a potential upside of 42.50% from the company’s current price.

The analysts wrote, “BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances.””

Separately, Zacks Investment Research lowered shares of Beigene from a “buy” rating to a “hold” rating in a report on Tuesday, January 17th.

Beigene (NASDAQ:BGNE) traded down 1.24% on Thursday, reaching $36.49. The company’s stock had a trading volume of 55,245 shares. Beigene has a 52 week low of $24.53 and a 52 week high of $42.09. The firm has a 50 day moving average price of $37.95 and a 200 day moving average price of $35.01. The stock’s market capitalization is $1.46 billion.

Beigene (NASDAQ:BGNE) last posted its earnings results on Wednesday, March 22nd. The company reported ($1.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by $0.19. The company had revenue of $1 million for the quarter, compared to analyst estimates of $3.75 million. The company’s quarterly revenue was down 78.6% on a year-over-year basis. During the same quarter last year, the firm earned ($3.05) EPS. On average, equities analysts anticipate that Beigene will post ($3.92) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Beigene Ltd (BGNE) Given Buy Rating at Maxim Group” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/05/13/beigene-ltd-bgne-given-buy-rating-at-maxim-group.html.

In other Beigene news, Director Xiaodong Wang sold 14,461 shares of the business’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $40.80, for a total value of $590,008.80. Following the transaction, the director now owns 65,030 shares in the company, valued at approximately $2,653,224. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Oyler sold 64,963 shares of the business’s stock in a transaction on Tuesday, February 21st. The stock was sold at an average price of $40.55, for a total transaction of $2,634,249.65. Following the completion of the transaction, the chief executive officer now owns 378,383 shares in the company, valued at approximately $15,343,430.65. The disclosure for this sale can be found here. Insiders sold a total of 381,561 shares of company stock worth $15,180,155 in the last quarter.

Several large investors have recently added to or reduced their stakes in the company. Boxer Capital LLC increased its stake in Beigene by 72.2% in the fourth quarter. Boxer Capital LLC now owns 850,000 shares of the company’s stock valued at $25,806,000 after buying an additional 356,370 shares during the last quarter. Guggenheim Capital LLC bought a new stake in Beigene during the fourth quarter valued at $670,000. Baillie Gifford & Co. increased its stake in Beigene by 0.7% in the fourth quarter. Baillie Gifford & Co. now owns 69,284 shares of the company’s stock valued at $2,103,000 after buying an additional 449 shares during the last quarter. Baker BROS. Advisors LP bought a new stake in Beigene during the third quarter valued at $58,930,000. Finally, Hsbc Holdings PLC bought a new stake in Beigene during the third quarter valued at $636,000. 33.01% of the stock is owned by institutional investors.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

5 Day Chart for NASDAQ:BGNE

Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.